Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||BRAF V600E MAP2K1 K57T|
|Indication/Tumor Type||hairy cell leukemia|
|Response Type||predicted - resistant|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E MAP2K1 K57T||hairy cell leukemia||predicted - resistant||Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).||30341394|
|PubMed Id||Reference Title||Details|
|(30341394)||Targeting MEK in vemurafenib-resistant hairy cell leukemia.||Full reference...|